Vildagliptin (X) [27] and Saxagliptin (XI) [28] are members of a new class of oral hypoglycemic agents known as dipeptidyl peptidase IV (DPP-IV) inhibitors, which were approved for the treatment of type 2 diabetes [29]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.